Impact Of Higher Part D Donut Hole Discounts Beginning To Show: Xarelto Sales Down 19%
Performance of Johnson & Johnson’s blockbuster cardiovascular drug is one of the first prominent examples of how the 2019 increase in the discount from 50% to 70% is playing out in the market.
You may also be interested in...
Government price 'negotiations' unlikely to be enacted in the near term, CEO Ricks tells investors, but reform of the Part D benefit also faces long odds, even though Lilly would support well designed changes.
With no legislative remedy in sight, the Medicare Part D out-of-pocket payment threshold will increase by $1,250 in 2020, causing many beneficiaries to linger longer in the coverage gap, where manufacturers provide 70% discounts on branded drugs.
As earnings season reaches its peak, Merck, Lilly, Gilead, Amgen and Sanofi release their second quarter results. Business development remains a dominant theme.